Skip to main content
    • Aa
    • Aa
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 18
  • Cited by
    This article has been cited by the following publications. This list is generated based on data provided by CrossRef.

    Hochberger, W.C. Hill, S.K. Nelson, C.L.M. Reilly, J.L. Keefe, R.S.E. Pearlson, G.D. Keshavan, M.S. Tamminga, C.A. Clementz, B.A. and Sweeney, J.A. 2016. Unitary construct of generalized cognitive ability underlying BACS performance across psychotic disorders and in their first-degree relatives. Schizophrenia Research, Vol. 170, Issue. 1, p. 156.

    Balzan, Ryan P. Neaves, Aaron Denson, Linley A. Liu, Dennis and Galletly, Cherrie 2014. Cognitive deficit awareness in schizophrenia: absent, intact, or somewhere in-between?. Cognitive Neuropsychiatry, Vol. 19, Issue. 6, p. 471.

    Barch, Deanna M. and Sheffield, Julia M. 2014. Cognitive impairments in psychotic disorders: common mechanisms and measurement. World Psychiatry, Vol. 13, Issue. 3, p. 224.

    Bliksted, Vibeke Fagerlund, Birgitte Weed, Ethan Frith, Chris and Videbech, Poul 2014. Social cognition and neurocognitive deficits in first-episode schizophrenia. Schizophrenia Research, Vol. 153, Issue. 1-3, p. 9.

    Keefe, Richard S.E. Fox, Kolleen H. Davis, Vicki G. Kennel, Courtney Walker, Trina M. Burdick, Katherine E. and Harvey, Philip D. 2014. The Brief Assessment of Cognition In Affective Disorders (BAC-A):Performance of patients with bipolar depression and healthy controls. Journal of Affective Disorders, Vol. 166, p. 86.

    Reilly, J. L. and Sweeney, J. A. 2014. Generalized and Specific Neurocognitive Deficits in Psychotic Disorders: Utility for Evaluating Pharmacological Treatment Effects and as Intermediate Phenotypes for Gene Discovery. Schizophrenia Bulletin, Vol. 40, Issue. 3, p. 516.

    Thorsen, Anders Lillevik Johansson, Kyrre and Løberg, Else-Marie 2014. Neurobiology of Cognitive Remediation Therapy for Schizophrenia: A Systematic Review. Frontiers in Psychiatry, Vol. 5,

    Barch, Deanna M. Bustillo, Juan Gaebel, Wolfgang Gur, Raquel Heckers, Stephan Malaspina, Dolores Owen, Michael J. Schultz, Susan Tandon, Rajiv Tsuang, Ming Van Os, Jim and Carpenter, William 2013. Logic and justification for dimensional assessment of symptoms and related clinical phenomena in psychosis: Relevance to DSM-5. Schizophrenia Research, Vol. 150, Issue. 1, p. 15.

    Eng, G. K. Lam, M. Bong, Y. L. Subramaniam, M. Bautista, D. Rapisarda, A. Kraus, M. Lee, J. Collinson, S. L. Chong, S. A. and Keefe, R. S. E. 2013. Brief Assessment of Cognition in Schizophrenia: Normative Data in an English-Speaking Ethnic Chinese Sample. Archives of Clinical Neuropsychology, Vol. 28, Issue. 8, p. 845.

    Hill, S. Kristian Bjorkquist, Olivia Carrathers, Tarra Roseberry, Jarett E. Hochberger, William C. and Bishop, Jeffrey R. 2013. Sequential processing deficits in schizophrenia: Relationship to neuropsychology and genetics. Schizophrenia Research, Vol. 151, Issue. 1-3, p. 91.

    Mehta, Urvakhsh Meherwan Thirthalli, Jagadisha Subbakrishna, D.K. Gangadhar, Bangalore N. Eack, Shaun M. and Keshavan, Matcheri S. 2013. Social and neuro-cognition as distinct cognitive factors in schizophrenia: A systematic review. Schizophrenia Research, Vol. 148, Issue. 1-3, p. 3.

    Hurford, I. M. Marder, S. R. Keefe, R. S. E. Reise, S. P. and Bilder, R. M. 2011. A Brief Cognitive Assessment Tool for Schizophrenia: Construction of a Tool for Clinicians. Schizophrenia Bulletin, Vol. 37, Issue. 3, p. 538.

    Sachs, G. Winklbaur, B. Jagsch, R. and Keefe, R.S.E. 2011. Validation of the German Version of the Brief Assessment of Cognition in Schizophrenia (BACS) – Preliminary Results. European Psychiatry, Vol. 26, Issue. 2, p. 74.

    Hill, S Kristian Bishop, Jeffrey R Palumbo, Donna and Sweeney, John A. 2010. Effect of second-generation antipsychotics on cognition: current issues and future challenges. Expert Review of Neurotherapeutics, Vol. 10, Issue. 1, p. 43.

    Hooper, Stephen R. Giuliano, Anthony J. Youngstrom, Eric A. Breiger, David Sikich, Linmarie Frazier, Jean A. Findling, Robert L. McClellan, Jon Hamer, Robert M. Vitiello, Benedetto and Lieberman, Jeffrey A. 2010. Neurocognition in Early-Onset Schizophrenia and Schizoaffective Disorders. Journal of the American Academy of Child & Adolescent Psychiatry, Vol. 49, Issue. 1, p. 52.

    Hooper, Stephen R. Giuliano, Anthony J. Youngstrom, Eric A. Breiger, David Sikich, Linmarie Frazier, Jean A. Findling, Robert L. McClellan, Jon Hamer, Robert M. Vitiello, Benedetto and Lieberman, Jeffrey A. 2010. Neurocognition in Early-Onset Schizophrenia and Schizoaffective Disorders. Journal of the American Academy of Child & Adolescent Psychiatry, Vol. 49, Issue. 1, p. 52.

    Pietrzak, Robert H. Olver, James Norman, Trevor Piskulic, Danijela Maruff, Paul and Snyder, Peter J. 2009. A comparison of the CogState Schizophrenia Battery and the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Battery in assessing cognitive impairment in chronic schizophrenia. Journal of Clinical and Experimental Neuropsychology, Vol. 31, Issue. 7, p. 848.

    Keefe, R. S. E. and Harvey, P. D. 2007. Implementation Considerations for Multisite Clinical Trials with Cognitive Neuroscience Tasks. Schizophrenia Bulletin, Vol. 34, Issue. 4, p. 656.

  • Journal of the International Neuropsychological Society, Volume 14, Issue 2
  • March 2008, pp. 209-221

Efficiency of the CATIE and BACS neuropsychological batteries in assessing cognitive effects of antipsychotic treatments in schizophrenia

  • DOI:
  • Published online: 01 February 2008

Efficient and reliable assessments of cognitive treatment effects are essential for the comparative evaluation of procognitive effects of pharmacologic therapies. Yet, no studies have addressed the sensitivity and efficiency with which neurocognitive batteries evaluate cognitive abilities before and after treatment. Participants were primarily first episode schizophrenia patients who completed baseline (n = 367) and 12-week (n = 219) assessments with the BACS (Brief Assessment of Cognition in Schizophrenia) and CATIE (Clinical Antipsychotic Trials of Intervention Effectiveness) neuropsychological batteries in a clinical trial comparing olanzapine, quetiapine, and risperidone. Exploratory factor analysis revealed that performance on both batteries was characterized by a single factor of generalized cognitive deficit for both baseline performance and cognitive change after treatment. Both batteries estimated similar levels of change following treatment, although the BACS battery required half the administration time. Because a unitary factor characterized baseline cognitive abilities in early psychosis as well as cognitive change after treatment with atypical antipsychotic medications, short batteries such as the BACS may efficiently provide sufficient assessment of procognitive treatment effects with antipsychotic medications. Assessment of cognitive effects of adjunctive therapies targeting specific cognitive domains or impairments may require more extensive testing of the domains targeted to maximize sensitivity for detecting specific predicted cognitive outcomes. (JINS, 2008, 14, 209–221.)Presented in part at the annual International Neuropsychology Society meeting in Portland, OR, February 2007; and the 2007 International Congress for Schizophrenia Research in Colorado Springs, CO.

Corresponding author
Correspondence and reprint requests to: Dr. S. Kristian Hill, University of Illinois at Chicago, Center for Cognitive Medicine, Department of Psychiatry (M/C 913), 912 South Wood Street, Suite 235, Chicago, IL 60612. E-mail:
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Journal of the International Neuropsychological Society
  • ISSN: 1355-6177
  • EISSN: 1469-7661
  • URL: /core/journals/journal-of-the-international-neuropsychological-society
Please enter your name
Please enter a valid email address
Who would you like to send this to? *